CORONA Remedies Q3 FY26: PAT up 23.7%, revenue up 15%

Profit growth above 25%Exceptional itemResults View source PDF Explain this filing

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.1%Reaction day

₹1460.00

prior close

₹1459.60

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+3.7%-0.6% vs market

Pharmaceuticals peers, median of 157sector+2.6%+0.5% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

-0.9

15m

-1.2

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.1+3.7-0.6+2.6+0.5

Next day

+0.8+5.1-4.3+2.6-1.9

+5.1+4.0+1.1+1.6+3.5

+5.5+3.2+2.3+1.1+4.4

+11.5+5.9+5.6+2.9+8.6

+11.7+6.9+4.8+3.1+8.6

+10.6+5.9+4.7+2.5+8.0

15d

+9.3+2.1+7.3-0.7+10.0

+6.2-3.5+9.6-2.7+8.8

+1.9-4.2+6.2-4.8+6.8

+18.8+10.9+7.9+4.0+14.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q3 FY26 revenue from operations stood at Rs 342.42 Cr, up 15% YoY. 9M FY26 revenue was Rs 1,050.09 Cr, up 16.3% YoY. Q3 EBITDA was Rs 83.16 Cr with 24.3% margin. PAT grew 23.7% YoY to Rs 55.56 Cr in Q3 and 30.7% YoY to Rs 154.08 Cr for 9M. PAT excludes a one-time Rs 19.10 Cr impact from the new labour code. RoE stood at 31.1% and RoCE at 48% on annualised basis. CEO Mehta said the company has consistently delivered on its 15% revenue and 20% PAT growth guidance across 3 quarters.

Likely market impact

Strong revenue and PAT growth with healthy margins and return ratios. PAT growth has consistently exceeded guidance. Excludes one-time labour code impact.